

### Amendments to the Claims


This listing of claims will replace all prior versions, and listings, of claims in the application:

#### Listing of Claims:

1-10 (Cancelled)





11. (New)

A compound of the formula shown below:




wherein Z = aryl, heterocyclic, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl group, while X and Y can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group except the compounds with:

X	Y	Z
H, methyl, benzyl	H	phenyl
methyl	H	4-pyridine

methyl	methyl	$-\text{CH}_2\text{CH}=\text{CHPh}$
benzyl	methyl	$-\text{CH}_2\text{CH}=\text{CHPh}$
benzyl	H	$-\text{CH}_2\text{CH}=\text{CHPh}$
methyl	H	
methyl	H	
is selected from hydrogen, (C <sub>1-6</sub> )alkyl, (C <sub>3-7</sub> )cycloalkyl, (C <sub>2-6</sub> )aklenyl, aryl, aryl(C <sub>1-4</sub> )alkyl, heterocyclyl	is selected from hydrogen, (C <sub>1-6</sub> )alkyl, (C <sub>3-7</sub> )cycloalkyl, (C <sub>2-6</sub> )alkenyl, aryl, aryl(C <sub>1-4</sub> )alkyl, heterocyclyl, and is the same or different from X	 or  wherein A is a group of atoms for linking C(O)O with CONY.

12. (New)

A compound according to claim 11, wherein




, wherein Z<sub>1</sub> is a group with at least two hydrophilic atoms selected from N or O.

13. (New)

A compound according to claim 12, wherein Z<sub>1</sub> is piperazinyl, 4-methyl-piperazinyl or morphoninyl.

14. (New)

A method of treating or preventing proliferative diseases in a human or an animal comprising administration to the human or animal of a therapeutic amount of a compound of the formula shown below:



wherein Z = aryl, heterocyclic, substituted or unsubstituted alkenyl, substituted or unsubstituted alkynyl group, while X and Y can be the same or different, are hydrogen, substituted or unsubstituted alkyl, cycloalkyl, aryl, aralkyl or heterocyclic group.

15. (New)

A pharmaceutical composition comprising a compound as defined in any one of claims 11 to 13 or a pharmaceutically acceptable salt thereof, in association with a pharmaceutical carrier or diluent.